Saturday, 31 March 2018

Mixing, diluting, or repackaging biological products outside the scope of an approved Biologics License Application

This final guidance sets forth FDA’s policy regarding the mixing, diluting, and repackaging
of certain types of biological products that have been licensed under section 351 of the Public Health Service Act (PHS Act) when such activities are not within the scope of the product’s approved biologics license application (BLA) as described in the approved labeling for the product.

Posted by Dr. Tim Sandle

No comments:

Post a Comment

Pharmaceutical Microbiology Resources

Special offers